Marina Mata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marina Mata has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- David J. Finkl
Department of Neurology, University of Michigan and VA Ann Arbor Healthcare System, Ann Arbor, MI, USA
8 shared publications David J. Fink
Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA
7 shared publicationsZhigang Zhou
Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA
6 shared publicationsXiangmin Peng
5 shared publications- Joseph C. Glorioso
Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
3 shared publications - Ryan Insolera
Wayne State University
3 shared publications
Latest Publications
- 16 October 2013
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 57, 111-119
HspB1 silences translation of PDZ-RhoGEF by enhancing miR-20a and miR-128 expression to promote neurite extension
- 16 October 2013
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 57, 111-119
HspB1 silences translation of PDZ-RhoGEF by enhancing miR-20a and miR-128 expression to promote neurite extension
- Open Access
- 6 July 2013
- Published by Springer Nature in Molecular Brain
- Vol. 6 (1) , 30
Post-transcriptional regulation of GABAB receptor and GIRK1 channels by Nogo receptor 1
Background: Type B GABA receptors (GABA Rs) play a critical role in synaptic transmission. We carried out studies to determine whether neuronal cell surface expression of GABAB-Rs might be regulated by the Nogo receptor 1 (NgR1). Results: siRNA knock-down of NgR1 resulted in a selective increase of GABAB R1 and GABAB R2 protein without altering the expression of GABAA receptor or GAD65. The increase in GABAB receptor subunits was unaccompanied by a change in mRNA, but inhibition of mTOR by rapamycin blocked the increase in GABAB protein. NgR1 siRNA also caused an increase in G protein coupled inwardly rectifying potassium channel (GIRK1). The increase in GABAB receptor and GIRK1 channel proteins was in the plasma membrane, determined by cell surface biotinylation. In NgR1 knockout mice, the amount of GABAB R2 and GIRK1 in hippocampus-derived synaptosomes was increased. Conclusions: Together these findings suggest that NgR1 mediated modulation of synaptic transmission may be accomplished, at least in part, through modulation of G protein coupled receptors and channels.
- 6 July 2013
- Published by Springer Nature in Molecular Brain
- Vol. 6 (1) , 30
Open AccessPost-transcriptional regulation of GABAB receptor and GIRK1 channels by Nogo receptor 1
Background: Type B GABA receptors (GABA Rs) play a critical role in synaptic transmission. We carried out studies to determine whether neuronal cell surface expression of GABAB-Rs might be regulated by the Nogo receptor 1 (NgR1). Results: siRNA knock-down of NgR1 resulted in a selective increase of GABAB R1 and GABAB R2 protein without altering the expression of GABAA receptor or GAD65. The increase in GABAB receptor subunits was unaccompanied by a change in mRNA, but inhibition of mTOR by rapamycin blocked the increase in GABAB protein. NgR1 siRNA also caused an increase in G protein coupled inwardly rectifying potassium channel (GIRK1). The increase in GABAB receptor and GIRK1 channel proteins was in the plasma membrane, determined by cell surface biotinylation. In NgR1 knockout mice, the amount of GABAB R2 and GIRK1 in hippocampus-derived synaptosomes was increased. Conclusions: Together these findings suggest that NgR1 mediated modulation of synaptic transmission may be accomplished, at least in part, through modulation of G protein coupled receptors and channels.
- 1 September 2012
- Published by Elsevier in Experimental Neurology
- Vol. 237 (1) , 126-133
HSV-mediated gene transfer of C3 transferase inhibits Rho to promote axonal regeneration
- 1 September 2012
- Published by Elsevier in Experimental Neurology
- Vol. 237 (1) , 126-133
HSV-mediated gene transfer of C3 transferase inhibits Rho to promote axonal regeneration
- Open Access
- 1 January 2012
- Published by SAGE Publications in Molecular Pain
- Vol. 8, 17
Reduction of Voltage Gated Sodium Channel Protein in DRG by Vector Mediated miRNA Reduces Pain in Rats with Painful Diabetic Neuropathy
Background: Painful neuropathy is a common complication of diabetes. Previous studies have identified significant increases in the amount of voltage gated sodium channel isoforms NaV1.7 and NaV1.3 protein in the dorsal root ganglia (DRG) of rats with streptozotocin (STZ)-induced diabetes. We found that gene transfer-mediated release of the inhibitory neurotransmitters enkephalin or gamma amino butyric acid (GABA) from DRG neurons in diabetic animals reduced pain-related behaviors coincident with a reduction in NaV1.7 protein levels in DRG in vivo. To further evaluate the role of NaVα subunit levels in DRG in the pathogenesis of pain in diabetic neuropathy, we constructed a nonreplicating herpes simplex virus (HSV)-based vector expressing a microRNA (miRNA) against NaVα subunits. Results: Subcutaneous inoculation of the miRNA-expressing HSV vector into the feet of diabetic rats to transduce DRG resulted in a reduction in NaVα subunit levels in DRG neurons, coincident with a reduction in cold allodynia, thermal hyperalgesia and mechanical hyperalgesia. Conclusions: These data support the role of increased NaVα protein in DRG in the pathogenesis of pain in diabetic neuropathy, and provide a proof-of-principle demonstration for the development of a novel therapy that could be used to treat intractable pain in patients with diabetic neuropathy.
- 1 January 2012
- Published by SAGE Publications in Molecular Pain
- Vol. 8, 17
Open AccessReduction of Voltage Gated Sodium Channel Protein in DRG by Vector Mediated miRNA Reduces Pain in Rats with Painful Diabetic Neuropathy
Background: Painful neuropathy is a common complication of diabetes. Previous studies have identified significant increases in the amount of voltage gated sodium channel isoforms NaV1.7 and NaV1.3 protein in the dorsal root ganglia (DRG) of rats with streptozotocin (STZ)-induced diabetes. We found that gene transfer-mediated release of the inhibitory neurotransmitters enkephalin or gamma amino butyric acid (GABA) from DRG neurons in diabetic animals reduced pain-related behaviors coincident with a reduction in NaV1.7 protein levels in DRG in vivo. To further evaluate the role of NaVα subunit levels in DRG in the pathogenesis of pain in diabetic neuropathy, we constructed a nonreplicating herpes simplex virus (HSV)-based vector expressing a microRNA (miRNA) against NaVα subunits. Results: Subcutaneous inoculation of the miRNA-expressing HSV vector into the feet of diabetic rats to transduce DRG resulted in a reduction in NaVα subunit levels in DRG neurons, coincident with a reduction in cold allodynia, thermal hyperalgesia and mechanical hyperalgesia. Conclusions: These data support the role of increased NaVα protein in DRG in the pathogenesis of pain in diabetic neuropathy, and provide a proof-of-principle demonstration for the development of a novel therapy that could be used to treat intractable pain in patients with diabetic neuropathy.
- Open Access
- 3 November 2011
- Published by Springer Nature in Gene Therapy
- Vol. 19 (9) , 907-914
Vector-mediated expression of erythropoietin improves functional outcome after cervical spinal cord contusion injury
We evaluated the therapeutic effect of erythropoietin (EPO) delivered by direct injection of a nonreplicating herpes simplex virus (HSV)-based vector coding for EPO (vEPO) in a model of cervical hemicord contusion at C7. At 1 h after spinal cord injury (SCI), either vEPO or control vector carrying a reporter gene (vC) was injected into the cord above and below the lesion. Animals injected with vEPO showed a statistically significant improvement in the ipsilateral forelimb function, as measured by open-field evaluation of motor performance, forelimb reaching in the cylinder test and misplacement in grid walk. This correlated with preservation of gray matter in the area of the lesion. There was also mild but significant improvement of hindlimb motor function measured by Basso–Beattie–Bresnahan score and computerized gait analysis in vEPO compared with control vector-injected animals. Microtubule-associated protein tau, phosphorylated and nonphosphorylated neurofilament protein and the synaptic proteins synaptophysin and PSD-95 were all significantly increased in the spinal cord of vEPO-treated animals compared with control vector-injected animals. These data suggest that gene transfer of EPO after cervical SCI by minimizing the injury size and enhancing tissue sparing preserves large-caliber axons and promotes synaptogenesis.
- 3 November 2011
- Published by Springer Nature in Gene Therapy
- Vol. 19 (9) , 907-914
Open AccessVector-mediated expression of erythropoietin improves functional outcome after cervical spinal cord contusion injury
We evaluated the therapeutic effect of erythropoietin (EPO) delivered by direct injection of a nonreplicating herpes simplex virus (HSV)-based vector coding for EPO (vEPO) in a model of cervical hemicord contusion at C7. At 1 h after spinal cord injury (SCI), either vEPO or control vector carrying a reporter gene (vC) was injected into the cord above and below the lesion. Animals injected with vEPO showed a statistically significant improvement in the ipsilateral forelimb function, as measured by open-field evaluation of motor performance, forelimb reaching in the cylinder test and misplacement in grid walk. This correlated with preservation of gray matter in the area of the lesion. There was also mild but significant improvement of hindlimb motor function measured by Basso–Beattie–Bresnahan score and computerized gait analysis in vEPO compared with control vector-injected animals. Microtubule-associated protein tau, phosphorylated and nonphosphorylated neurofilament protein and the synaptic proteins synaptophysin and PSD-95 were all significantly increased in the spinal cord of vEPO-treated animals compared with control vector-injected animals. These data suggest that gene transfer of EPO after cervical SCI by minimizing the injury size and enhancing tissue sparing preserves large-caliber axons and promotes synaptogenesis.
- Open Access
- 10 October 2011
- Published by Wiley in Journal of Neurochemistry
- Vol. 119 (6) , 1183-1193
Neuronal Nogo‐A regulates glutamate receptor subunit expression in hippocampal neurons
J. Neurochem.(2011) 10.1111/j.1471‐4159.2011.07520.x Nogo‐A and its cognate receptor NogoR1 (NgR1) are both expressed in neurons. To explore the function of these proteins in neurons of the CNS, we carried out a series of studies using postnatal hippocampal neurons in culture. Interfering with the binding of Nogo‐A to NgR1 either by adding truncated soluble fragment of NgR1 (NgSR) or by reducing NgR1 protein with a specific siRNA, resulted in a marked reduction in Nogo‐A expression. Inhibition of Rho‐ROCK or MEK‐MAPK signaling resulted in a similar reduction in neuronal Nogo‐A mRNA and protein. Reducing Nogo‐A protein levels by siRNA resulted in an increase in the post‐synaptic scaffolding protein PSD95, as well as increases in GluA1/GluA2 AMPA receptor and GluN1/GluN2A/GluN2B NMDA glutamate receptor subunits. siRNA treatment to reduce Nogo‐A resulted in phosphorylation of mTOR; addition of rapamycin to block mTOR signaling prevented the up‐regulation in glutamate receptor subunits. siRNA reduction of NgR1 resulted in increased expression of the same glutamate receptor subunits. Taken together the results suggest that transcription and translation of Nogo‐A in hippocampal neurons is regulated by a signaling through NgR1, and that interactions between neuronal Nogo‐A and NgR1 regulate glutamatergic transmission by altering NMDA and AMPA receptor levels through an rapamycin‐sensitive mTOR‐dependent translation mechanism.
- 10 October 2011
- Published by Wiley in Journal of Neurochemistry
- Vol. 119 (6) , 1183-1193
Open AccessNeuronal Nogo‐A regulates glutamate receptor subunit expression in hippocampal neurons
J. Neurochem.(2011) 10.1111/j.1471‐4159.2011.07520.x Nogo‐A and its cognate receptor NogoR1 (NgR1) are both expressed in neurons. To explore the function of these proteins in neurons of the CNS, we carried out a series of studies using postnatal hippocampal neurons in culture. Interfering with the binding of Nogo‐A to NgR1 either by adding truncated soluble fragment of NgR1 (NgSR) or by reducing NgR1 protein with a specific siRNA, resulted in a marked reduction in Nogo‐A expression. Inhibition of Rho‐ROCK or MEK‐MAPK signaling resulted in a similar reduction in neuronal Nogo‐A mRNA and protein. Reducing Nogo‐A protein levels by siRNA resulted in an increase in the post‐synaptic scaffolding protein PSD95, as well as increases in GluA1/GluA2 AMPA receptor and GluN1/GluN2A/GluN2B NMDA glutamate receptor subunits. siRNA treatment to reduce Nogo‐A resulted in phosphorylation of mTOR; addition of rapamycin to block mTOR signaling prevented the up‐regulation in glutamate receptor subunits. siRNA reduction of NgR1 resulted in increased expression of the same glutamate receptor subunits. Taken together the results suggest that transcription and translation of Nogo‐A in hippocampal neurons is regulated by a signaling through NgR1, and that interactions between neuronal Nogo‐A and NgR1 regulate glutamatergic transmission by altering NMDA and AMPA receptor levels through an rapamycin‐sensitive mTOR‐dependent translation mechanism.
- 1 September 2011
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 48 (1) , 29-37
Rho GTPase regulation of α-synuclein and VMAT2: Implications for pathogenesis of Parkinson's disease
- 1 September 2011
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 48 (1) , 29-37
Rho GTPase regulation of α-synuclein and VMAT2: Implications for pathogenesis of Parkinson's disease
- Open Access
- 1 January 2011
- Published by SAGE Publications in Molecular Pain
- Vol. 7 (1) , 40
Glial TNFα in the Spinal Cord Regulates Neuropathic Pain Induced by HIV gp120 Application in Rats
Background: HIV-associated sensory neuropathy (HIV-SN) is one of the most common forms of peripheral neuropathy, affecting about 30% of people with acquired immune deficiency syndrome (AIDS). The symptoms of HIV-SN are dominated by neuropathic pain. Glia activation in the spinal cord has become an attractive target for attenuating chronic pain. This study will investigate the role of spinal TNFα released from glia in HIV-related neuropathic pain.Results: Peripheral gp120 application into the rat sciatic nerve induced mechanical allodynia for more than 7 weeks, and upregulated the expression of spinal TNFα in the mRNA and the protein levels at 2 weeks after gp120 application. Spinal TNFα was colocalized with GFAP (a marker of astrocytes) and Iba1 (a marker of microglia) in immunostaining, suggesting that glia produce TNFα in the spinal cord in this model. Peripheral gp120 application also increased TNFα in the L4/5 DRG. Furthermore, intrathecal administration of TNFα siRNA or soluble TNF receptor reduced gp120 application-induced mechanical allodynia.Conclusions: Our results indicate that TNFα in the spinal cord and the DRG are involved in neuropathic pain, following the peripheral HIV gp120 application, and that blockade of the glial product TNFα reverses neuropathic pain induced by HIV gp120 application.
- 1 January 2011
- Published by SAGE Publications in Molecular Pain
- Vol. 7 (1) , 40
Open AccessGlial TNFα in the Spinal Cord Regulates Neuropathic Pain Induced by HIV gp120 Application in Rats
Background: HIV-associated sensory neuropathy (HIV-SN) is one of the most common forms of peripheral neuropathy, affecting about 30% of people with acquired immune deficiency syndrome (AIDS). The symptoms of HIV-SN are dominated by neuropathic pain. Glia activation in the spinal cord has become an attractive target for attenuating chronic pain. This study will investigate the role of spinal TNFα released from glia in HIV-related neuropathic pain.Results: Peripheral gp120 application into the rat sciatic nerve induced mechanical allodynia for more than 7 weeks, and upregulated the expression of spinal TNFα in the mRNA and the protein levels at 2 weeks after gp120 application. Spinal TNFα was colocalized with GFAP (a marker of astrocytes) and Iba1 (a marker of microglia) in immunostaining, suggesting that glia produce TNFα in the spinal cord in this model. Peripheral gp120 application also increased TNFα in the L4/5 DRG. Furthermore, intrathecal administration of TNFα siRNA or soluble TNF receptor reduced gp120 application-induced mechanical allodynia.Conclusions: Our results indicate that TNFα in the spinal cord and the DRG are involved in neuropathic pain, following the peripheral HIV gp120 application, and that blockade of the glial product TNFα reverses neuropathic pain induced by HIV gp120 application.
- Open Access
- 3 March 2010
- Published by Wiley in Journal of Neurochemistry
- Vol. 113 (1) , 143-152
Transgene‐mediated GDNF expression enhances synaptic connectivity and GABA transmission to improve functional outcome after spinal cord contusion
J. Neurochem. (2010) 10.1111/j.1471‐4159.2010.06593.x Glial cell line‐derived trophic factor (GDNF) is a peptide with pleiotropic survival and growth‐promoting effects on neurons. We found that intraspinal injection of a non‐replicating herpes simplex virus‐based vector coding for GDNF 2 h after blunt trauma to the thoraco‐lumbar spinal cord produced sustained improvement in motor behavioral outcomes up to 5 weeks following injury. The improvement in behavior correlated with an increase in synaptophysin and glutamic acid decarboxylase (GAD) in the spinal cord at the level of injury. Addition of recombinant GDNF protein to primary spinal cord neurons in‐vitro resulted in enhanced neurite growth and a marked increase in protein levels of GAD65 and GAD67, synapsin I and synaptophysin. GDNF‐mediated increases in GAD and the synaptic markers were blocked by the MEK inhibitor UO126, but not by the phosphoinositide 3‐kinase inhibitor LY294002. These results suggest that GDNF, acting through the MEK‐ERK pathway enhances axonal sprouting, synaptic connectivity, and GABAergic neurotransmission in the spinal cord, that result in improved behavioral outcomes after spinal cord contusion injury.
- 3 March 2010
- Published by Wiley in Journal of Neurochemistry
- Vol. 113 (1) , 143-152
Open AccessTransgene‐mediated GDNF expression enhances synaptic connectivity and GABA transmission to improve functional outcome after spinal cord contusion
J. Neurochem. (2010) 10.1111/j.1471‐4159.2010.06593.x Glial cell line‐derived trophic factor (GDNF) is a peptide with pleiotropic survival and growth‐promoting effects on neurons. We found that intraspinal injection of a non‐replicating herpes simplex virus‐based vector coding for GDNF 2 h after blunt trauma to the thoraco‐lumbar spinal cord produced sustained improvement in motor behavioral outcomes up to 5 weeks following injury. The improvement in behavior correlated with an increase in synaptophysin and glutamic acid decarboxylase (GAD) in the spinal cord at the level of injury. Addition of recombinant GDNF protein to primary spinal cord neurons in‐vitro resulted in enhanced neurite growth and a marked increase in protein levels of GAD65 and GAD67, synapsin I and synaptophysin. GDNF‐mediated increases in GAD and the synaptic markers were blocked by the MEK inhibitor UO126, but not by the phosphoinositide 3‐kinase inhibitor LY294002. These results suggest that GDNF, acting through the MEK‐ERK pathway enhances axonal sprouting, synaptic connectivity, and GABAergic neurotransmission in the spinal cord, that result in improved behavioral outcomes after spinal cord contusion injury.
- Open Access
- 1 January 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (4) , 2783-2795
Soluble Nogo Receptor Down-regulates Expression of Neuronal Nogo-A to Enhance Axonal Regeneration
- 1 January 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (4) , 2783-2795
Open AccessSoluble Nogo Receptor Down-regulates Expression of Neuronal Nogo-A to Enhance Axonal Regeneration